Journal issues > Issue 5, September 2021 > AML and MDS: a virtual experience of real world data

AML and MDS: a virtual experience of real world data

INTRODUCTION

The general poor prognosis of AML has stimulated the haematology society and industry to move forward in recent years. Because of these efforts, you could easily imagine yourself at a myeloma session during EHA2021. For patients non-eligible for intensive chemotherapy, the therapeutic arsenal has never been so wide and is constantly expanding. In Belgium, haematologists are bound to strict regulations making ‘game-changing’ data scarce at international congresses. However, the experts in the field shared their strategies in daily practice, which might be even more useful. Nevertheless, one rule remains that it is our duty to include patients in clinical trials whenever possible.

(BELG J HEMATOL 2021;12(5):197-200)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top